SIREN : 824585848
VB PHARMA is a French company founded 9 years ago, specialized in the sector Activités des sociétés holding. Based in FOIX (09000), this company of category PME shows in 2024 a net income positive of 127 k€. Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.
Data updated on 2026-05-02
Sources : INPI & INSEE SIRENE - Processing : Ministry of Economy
| Indicator | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|
| Revenue | N/C | N/C | N/C | N/C | N/C | N/C | N/C | N/C |
| Net income | 127 075 € | 93 267 € | 155 700 € | 75 217 € | 43 715 € | 27 364 € | 25 648 € | -10 825 € |
| EBITDA | -1 676 € | -5 140 € | -2 366 € | -2 511 € | -2 872 € | -3 076 € | -4 694 € | -9 752 € |
| Net margin | N/C | N/C | N/C | N/C | N/C | N/C | N/C | N/C |
In 2024, VB PHARMA generates positive net income of 127 k€. Net income represents the final profit after all expenses (operating, financial, exceptional) and corporate tax.
-1 676 €
-1 677 €
127 075 €
The debt ratio (= Financial debt / Equity x 100) stands at 24%. This very low level reflects a solid financial structure, offering significant room for future investments or acquisitions. Financial autonomy (= Equity / Total assets x 100) reaches 81%. This high autonomy means the company finances most of its assets through equity, a sign of strength. Debt repayment capacity (= Financial debt / Cash flow) indicates it would take 1.9 years of cash flow to repay all financial debt. This short period demonstrates excellent debt sustainability.
23.878%
80.691%
1.851
In 2024, the debt ratio of VB PHARMA (23.88) ranks above the median of the sector. This ratio measures the weight of debt relative to equity. A reduction effort could improve financial strength.
In 2024, the financial autonomy of VB PHARMA (80.7%) ranks above the median of the sector. This ratio represents the share of equity in total financing. This comfortable position offers an appreciable safety margin.
In 2024, the repayment capacity of VB PHARMA (1.85) ranks above the median of the sector. This ratio indicates the number of years needed to repay debt with cash flow. A reduction effort could improve financial strength.
The liquidity ratio (= Current assets / Current liabilities) stands at 10809.52. Concretely, the company has €2 of liquid assets for every €1 of short-term debt: no cash risk within 12 months.
10809.524
-74.403
In 2024, the liquidity ratio of VB PHARMA (10809.52) ranks in the top 25% of the sector. This ratio measures the ability to cover short-term debt with current assets. A ratio above 1 ensures comfortable coverage of short-term maturities.
In 2024, the interest coverage of VB PHARMA (-74.4x) ranks below the median of the sector. This ratio indicates how many times operating income covers interest expenses. An improvement would strengthen the competitive position.
Working capital requirement (WCR) measures the cash timing gap between customer collections and supplier/inventory payments. Average customer payment term: 0 days (formula: Customer receivables / Revenue incl. VAT x 360). Supplier term: 90 days. Excellent situation: suppliers finance 90 days of the operating cycle (retail model).
0 €
0 j
90 j
0 j
Based on 54 transactions of similar company sales
in 2024,
the value of VB PHARMA is estimated at
185 524 €
(range 118 324€ - 949 054€).
This multiples method compares the actual sale price of similar companies to their financial indicators (Revenue, EBITDA, Net Income). It provides a market-based indicative estimate.
Medium reliability: estimate to be confirmed with in-depth analysis.
Only this financial indicator is available for this company.
This estimate is based on the analysis of 54 actual transactions of similar company sales (same NAF code) registered with BODACC between 2016 and 2025.
This estimate is provided for information purposes only. A precise valuation requires in-depth analysis (assets, liabilities, prospects, market...).
Compare VB PHARMA with other companies in the same sector:
Voir toutes les statistiques du secteur Activités des sociétés holding
The revenue of VB PHARMA is not publicly disclosed (confidential accounts filed with INPI).
Yes, VB PHARMA generated a net profit of 127 k€ in 2024.
The headquarters of VB PHARMA is located in FOIX (09000), in the department Ariege.
The tax return of VB PHARMA is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).
VB PHARMA operates in the sector Activités des sociétés holding (NAF code 64.20Z). See the 'Sector positioning' section above to compare the company with its competitors.